Breaks Categories: News

ThursdayNov 12, 2020 12:03 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Reports Positive Preclinical Data on PH94B’s Mechanism of Action

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced new in vitro electrophysiology data. According to the update, the data demonstrate that the mechanism of action of PH94B, the intranasal neuroactive steroid the company is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder, does not involve direct activation of GABA-A receptors, in distinct contrast to the mechanism of action of benzodiazepines (“benzos”), which act as direct positive modulators of GABA-A receptors. “We are very pleased with…

Continue Reading

ThursdayNov 12, 2020 11:28 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Financial Results for Third Quarter

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released its financial results for Q3 2020. In addition, the company reported on important third-quarter highlights and provided an update on key objectives. Dario ended the third quarter with cash and cash equivalents of $37 million and plans to focus on its U.S. commercial sales and marketing infrastructure with the end goal of B2B2C pipeline growth. In addition, through its agreements with Vitality Group and HMC Healthworks, the company is committed to becoming a B2B2C digital therapeutics leader. The report also noted that Eric Milledge had been appointed…

Continue Reading

ThursdayNov 12, 2020 10:35 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosting Webcast for Discussion of Phase 2 Clinical Trial Design

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has scheduled a webcast today during which it will be discussing its plan to submit a phase 2 clinical trial design for FDA review. The call, which will be moderated by Robert LeBoyer, managing director of Equity Research at Ladenburg Thalmann & Co. Inc., will start at 4:30 p.m. ET. The phase 2 trial design is for the U.S. trial for CNSP’s Berubicin. Berubicin is the company’s lead drug candidate for the treatment of glioblastoma multiforme…

Continue Reading

WednesdayNov 11, 2020 11:21 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Life Sciences Summit Panel

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its senior vice president of intellectual property and licensing, Thomas Gallagher, will participate at the annual NYC-based Life Sciences Summit. Gallagher will take part in a panel discussion titled, “Show Me the Money: Preparing Your Company for Funding,” at the event, slated to place virtually November 17-18, 2020. During the panel discussion, scheduled for 10-10:45 a.m. ET on Tuesday, November 17, experts will provide insight into the essential building blocks needed for emerging companies to reach their goals.…

Continue Reading

TuesdayNov 10, 2020 2:40 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Completion of Strategic Merger

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. Prior to the merger’s closing, KBL Merger Corp. changed its name to 180 Life Sciences Corp., and 180 Life Sciences Corp. changed its name to 180 Life Corp., which now operates as a wholly owned subsidiary of the company. As a result of the merger, the units and rights of KBL Merger Corp. ceased trading, and the shares of its…

Continue Reading

TuesdayNov 10, 2020 1:10 pm

BioMedNewsBreaks – Antibe Therapeutics Inc. (TSXV: ATE) (OTCQB: ATBPF) Graduates to the TSX

Antibe Therapeutics (TSXV: ATE) (OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced its receipt of final approval from the Toronto Stock Exchange (“TSX”) to list its common shares on the TSX. According to the update, Antibe’s shares will commence TSX trading under the company’s existing ticker symbol “ATE” at market open on Thursday, November 12, 2020. “We are excited to graduate to the TSX, as it represents a further step in reaching the broader investment community while increasing liquidity for our shareholders,” said Dan Legault, Antibe’s…

Continue Reading

TuesdayNov 10, 2020 11:35 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Expands Scientific Advisory Board with Strategic Appointment

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (“SAB”). According to the update, Dr. Gittes is the inventor of GNPX’s licensed diabetes gene therapy technology that is currently in development and serves as the chief of pediatric surgery and surgeon-in-chief emeritus at the UPMC Children’s Hospital of Pittsburgh. “We are delighted to have Dr. Gittes join our Scientific Advisory Board as Genprex continues to advance its diabetes program,” said Rodney Varner, Genprex’s president and chief…

Continue Reading

TuesdayNov 10, 2020 11:12 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters LOI with Asymchem for MS1819 Development, Production

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced its entry into a binding letter of intent (“LOI”) with Asymchem, a leading global contract development and manufacturing service (“CDMO”) provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency. Under the agreement, Asymchem will implement fermentation, verify protein expression and ultimately fine-tune the technology suitable for production of MS1819. Asymchem will be responsible for sourcing all materials required for the program under Current Good Manufacturing Practice (“cGMP”) regulatory conditions. “With a fairly competitive landscape for CDMOs,…

Continue Reading

TuesdayNov 10, 2020 10:41 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Selected to Present at Upcoming Investor Conferences

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is slated to present at two upcoming investor conferences. Representing LexaGene at the conferences will be founder and CEO Jack Regan. Regan will be a presenter at the Investor Summit Group Conference held Nov. 18, 2020, at 1:30 p.m.  and at the Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum scheduled for Nov. 19, 2020, at 10 a.m. EST; additional information about these conferences and Regan’s presentations is available on the event page of LexaGene’s website.“This is an excellent opportunity for the Company…

Continue Reading

MondayNov 09, 2020 9:46 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Unveil Adaptive Design for Berubicin Phase 2 Clinical Trial in Nov. 12 Webinar

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its plans to issue a video update at 4:30 p.m. ET on Nov. 12, 2020, to discuss the clinical trial design for its upcoming Phase 2 U.S. trial for Berubicin. CNSP’s lead drug candidate – Berubicin – is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer, currently considered incurable. Robert LeBoyer, managing director of equity research at Ladenburg Thalmann & Co. Inc., will moderate the discussion.…

Continue Reading